CD38 and Miyoshi myopathy: Exploiting novel bi-molecular antibody derivatives coined hemibodies11, we demonstrate that MM regularly co-expresses CD38 and SLAMF7 antigens at high levels, which can be addressed by a combinatorial immunotherapy.